Immunoassays – Webinars and Online Events

Join our webinar, hosted by Klaus Hochleitner, to discuss key considerations for lateral flow test development and optimization and troubleshooting techniques for different samples, tests and antibodies.

The nitrocellulose membrane (NC) is the heart of a lateral flow assay. It is where the target and control molecules are captured and where the test results are read.
Join our webinar, hosted by Klaus Hochleitner, to take a deep dive into nitrocellulose membranes including the raw material, structure manufacturing process and capillary flow time and how these affect your lateral flow assays.
Klaus will also cover the effect of surfactants on protein binding and membrane properties and how to deal with unspecific binding of proteins to nitrocellulose membranes.

Speaking at Cell & Gene Therapy 2023,Tracy Zhao from ACROBiosystems, presented their talk on products and services across cell therapy research and development.

Speaking at Cell and Gene Therapy 2023, Habib Malik from Bio-Techne, presented their talk on reproducible and easy-to-use immunoassay platforms.

Off-the-shelf generic and commercial Chinese hamster ovaries (CHO) host cell proteins (HCP) ELISAs are commonly used to quantitate HCP in early process development. However, it’s challenging to find and choose a generic ELISA suited to a process.

In bioprocessing, it is critical that host cell proteins (HCPs) can be identified, detected and removed so that the efficacy of the drug is not impacted, and custom process-specific HCP ELISA are typically the preferred method for measuring these contaminants.

In this webinar, our expert speaker, Professor Lei Liu, Assistant Professor of Neurology from Harvard Medical School will discuss strategies in developing an ultrasensitive immunoassay* to measure oligomeric amyloid β in human plasma precisely.

Traditional Western blot workflows are notoriously labor-intensive and limited in reproducibility, quantification, sensitivity and multiplexing capabilities.

Join Dr Natalia Sannikova and Tomas Skrinskas from Ascension Sciences, as they explore the therapeutic use of cannabinoids as novel medicines and the opportunities of nanotechnology in formulating cannabinoid nanoparticles.

The manufacturing process for cell and gene therapies is complex and can contain process-related impurities from multiple organisms. A commercial host cell protein (HCP)-ELISA kit is often not available for the cell line or is not suitable for the specific process due to a low HCP coverage. Development of a process-specific ELISA can be unfeasible as the product often requires a short development time.